1. In Vivo
  2. >>Archive

DJ Orthopedics Expands in Rehabilitation

Often overlooked in all the interest in orthopedics is the non-surgical side, a product area that includes a wide range of supports and braces--soft goods as opposed to hard implants--used to treat a number of musculoskeletal problems. Indeed, given that non-surgical approaches represent an important front line in treatment options for patients with such problems-in spine, for example, surgical interventions are used in barely more than 10% of all patients complaining of back pain-it's surprising that more attention isn't paid to this segment. One company that has made the non-surgical orthopedics market a focus is dj Orthopedics Inc. who, with its acquisition of Aircast Inc. further enhances what is already a number-one market share position in the $1.2 billion US rehabilitation products market.

Over the past several years, the surgical side of orthopedics—most notably, total joint replacement and spine—have been among the device industry's best performing segments. Though orthopedic giants like Stryker Corp. , Zimmer Holdings Inc. , and Biomet Inc. took hits in 2005 due to concerns about potential pricing pressures and government scrutiny, orthopedic stocks had been trading at such a premium for the better part of a half decade that the sector overall has been one of the strongest from an investor's perspective.

Often overlooked in all the interest in orthopedics, however, is the non-surgical side, a product area that includes a wide...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.